Neurocrine Biosciences reported $1.12B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
ALKERMES USD 480.13M 15.88M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.4B 300M Sep/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Cytokinetics USD 47.6M 19M Sep/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Exelixis USD 658.69M 30M Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Prothena USD 1.01M 50.07M Jun/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Repligen USD 209M 5M Sep/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Teva Pharmaceutical Industries USD 4.37B 8.3B Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026